For instance, 10058-F4 characterization in vivo in severely combined immunodeficient (SCID) mice bearing DU145 and PC3 human prostate cancer xenografts, demonstrated the lack of efficacy and poor pharmacokinetic behavior of the specific Myc inhibitor in these classical models of moderate to high metastatic potential prostate cancer. This evidence concerns the gene MYC and prostate carcinoma.